Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial.

Asundexian added to antiplatelet therapy does not significantly increase major or overall bleeding in patients with noncardioembolic ischemic stroke or high-risk TIA.

• Why it matters: Understanding bleeding risks associated with new anticoagulants is crucial for balancing stroke prevention benefits against potential harms in this patient population.
• What they did: In a randomized trial of 12,254 participants, bleeding categories, sites, and subgroup effects were analyzed, focusing on major, CRNM, and minor bleeding events.
• The result: The study found no significant difference in major or CRNM bleeding between asundexian and placebo, though gastrointestinal bleeding, especially lower GI bleeding, was more frequent with asundexian.